ReviewInternational journal of chronic obstructive pulmonary disease2008
Pharmacoeconomics in COPD: lessons for the future.
Review in International journal of chronic obstructive pulmonary disease, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Cost-effectiveness of screening for chronic obstructive pulmonary disease: a systematic review and meta-analysis.BMC public health · 2025Pooled it
- Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations.PharmacoEconomics · 2017Pooled it
- Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.PharmacoEconomics · 2012Pooled it
- Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial.International journal of chronic obstructive pulmonary disease · 2022Trial
- Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis.Respiratory research · 2014Trial
- Estimating the Health and Economic Impact of Improved Management in Prevalent Chronic Obstructive Pulmonary Disease Populations in England, Germany, Canada, and Japan: A Modelling Study.International journal of chronic obstructive pulmonary disease · 2023Article
- Valuation of air pollution externalities: comparative assessment of economic damage and emission reduction under COVID-19 lockdown.Air quality, atmosphere, & health · 2020Article
- Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary care.Thorax · 2019Article
- Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.International journal of chronic obstructive pulmonary disease · 2019Article
- Estimating the extent and economic impact of under and overdiagnosis of chronic obstructive pulmonary disease in primary care.Chronic respiratory disease · 2016Observational
- Methodological reviews of economic evaluations in health care: what do they target?The European journal of health economics : HEPAC : health economics in prevention and care · 2014Article
- Improving clinical reality in chronic obstructive pulmonary disease economic modelling : development and validation of a micro-simulation approach.PharmacoEconomics · 2013Article
- New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses.PharmacoEconomics · 2012Review
- Scientific respiratory symposium, paris june 2010.Journal of asthma and allergy · 2011Article
- What is the impact of GOLD 2017 recommendations in primary care? - a descriptive study of patient classifications, treatment burden and costs.International journal of chronic obstructive pulmonary diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COPD exerts a substantial burden on health and health care systems globally and will continue to do so for the foreseeable future. Treatment however can be costly and health care providers are interested in both whether treatments can offer improvements in disease burden and whether they represent value for money. Economic evaluations seek to resolve this issue by producing results that can be used to inform and assist the decision maker in allocating scarce health care resources. In this paper we introduce economic evaluation and then use these themes to review and critically appraise the existing COPD economic evaluations, in order to assess quality in light of today's standards. The use of existing economic evaluations in informing the decision maker is then discussed. Ten out of the fifteen studies were clinical trial or observational study based, and the remaining five on a decision analytic model. Study design, interventions, outcome measures and the use of uncertainty varied considerably; consequentially the results are difficult to compare in any consistent manner. Efforts for future studies to harmonize study design and methodology, particularly towards adopting a modeling framework, using current treatment as comparator and adopting a common effectiveness measure, such as the QALY, should be made in order to produce results that are comparable and useful to a decision maker.
Indexed as
Identifiers
18488430PMC2528220What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.